AVXL vs. BASI, AMRX, DCPH, BHC, SNDX, CPRX, AMPH, ARVN, IMCR, and AKRO
Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Bioanalytical Systems (BASI), Amneal Pharmaceuticals (AMRX), Deciphera Pharmaceuticals (DCPH), Bausch Health Companies (BHC), Syndax Pharmaceuticals (SNDX), Catalyst Pharmaceuticals (CPRX), Amphastar Pharmaceuticals (AMPH), Arvinas (ARVN), Immunocore (IMCR), and Akero Therapeutics (AKRO). These companies are all part of the "medical" sector.
Bioanalytical Systems (NASDAQ:BASI) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking.
Bioanalytical Systems has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.
Bioanalytical Systems has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Bioanalytical Systems, indicating that it is currently the more affordable of the two stocks.
Anavex Life Sciences has a net margin of 0.00% compared to Anavex Life Sciences' net margin of -7.75%. Bioanalytical Systems' return on equity of -29.04% beat Anavex Life Sciences' return on equity.
Anavex Life Sciences received 298 more outperform votes than Bioanalytical Systems when rated by MarketBeat users. Likewise, 74.22% of users gave Anavex Life Sciences an outperform vote while only 40.38% of users gave Bioanalytical Systems an outperform vote.
In the previous week, Anavex Life Sciences had 11 more articles in the media than Bioanalytical Systems. MarketBeat recorded 11 mentions for Anavex Life Sciences and 0 mentions for Bioanalytical Systems. Bioanalytical Systems' average media sentiment score of 0.70 beat Anavex Life Sciences' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the news media.
10.6% of Bioanalytical Systems shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 11.5% of Bioanalytical Systems shares are held by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Anavex Life Sciences has a consensus target price of $40.00, indicating a potential upside of 493.47%. Given Bioanalytical Systems' higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Bioanalytical Systems.
Summary
Anavex Life Sciences beats Bioanalytical Systems on 10 of the 17 factors compared between the two stocks.
Get Anavex Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anavex Life Sciences Competitors List
Related Companies and Tools
